Genuv Inc. Report issue

For profit Phase 2
Founded: Seoul Korea, Republic of (2016)

Organization Overview

First Clinical Trial
2020
NCT04326283
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Genuv Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

riluzole (rilutek) (1 trial)

trametinib (mekinist) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Motor Neuron Disease (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2